Saltar al contenido
Merck

Exo1: a new chemical inhibitor of the exocytic pathway.

Proceedings of the National Academy of Sciences of the United States of America (2003-05-10)
Yan Feng, Sidney Yu, Troy K R Lasell, Ashutosh P Jadhav, Eric Macia, Pierre Chardin, Paul Melancon, Michael Roth, Timothy Mitchison, Tomas Kirchhausen
RESUMEN

A phenotypic screen was used to search for drug-like molecules that can interfere with specific steps in membrane traffic. 2-(4-Fluorobenzoylamino)-benzoic acid methyl ester (Exo1), identified in this screen, induces a rapid collapse of the Golgi to the endoplasmic reticulum, thus acutely inhibiting the traffic emanating from the endoplasmic reticulum. Like Brefeldin A (BFA), Exo1 induces the rapid release of ADP-ribosylation factor (ARF) 1 from Golgi membranes but has less effect on the organization of the trans-Golgi network. Our data indicate that Exo1 acts by a different mechanism from BFA. Unlike BFA, Exo1 does not induce the ADP-ribosylation of CtBP/Bars50 and does not interfere with the activity of guanine nucleotide exchange factors specific for Golgi-based ARFs. Thus, Exo1 allows the fatty acid exchange activity of Bars50 to be distinguished from ARF1 activity in the control of Golgi tubulation.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Exo 1, ≥98% (HPLC), solid